{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:03Z","timestamp":1793230623268,"version":"4.5.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["24ZR1477500"],"award-info":[{"award-number":["24ZR1477500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["CXTD2022011"],"award-info":[{"award-number":["CXTD2022011"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["LJ2021001"],"award-info":[{"award-number":["LJ2021001"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2024VBB0004"],"award-info":[{"award-number":["2024VBB0004"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341232"],"award-info":[{"award-number":["82341232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["083GJHZ2023021GC"],"award-info":[{"award-number":["083GJHZ2023021GC"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jconrel.2025.02.058","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T10:56:45Z","timestamp":1740221805000},"page":"113562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Nanobody-based drug delivery systems for cancer therapy"],"prefix":"10.1016","volume":"381","author":[{"given":"Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ergang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.02.058_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: Global estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0010","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-024-02970-3","article-title":"Artificial intelligence in surgery","volume":"30","author":"Varghese","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0015","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes & Diseas."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s44276-024-00064-8","article-title":"New light on chemotherapy toxicity and its prevention","volume":"2","author":"Juthani","year":"2024","journal-title":"BJC Report."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jaci.2018.02.042","article-title":"Immune checkpoint blockade therapy","volume":"142","author":"Wieder","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0040","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2147\/JMDH.S313968","article-title":"Targeted drug delivery - from magic bullet to nanomedicine: principles, challenges, and future perspectives","volume":"14","author":"Tewabe","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmedt.2019.00001","article-title":"Grand challenges in nano-based drug delivery","volume":"1","author":"Pasut","year":"2019","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120268","article-title":"Antibody-mediated drug delivery","volume":"596","author":"Arslan","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/mba2.54","article-title":"Recent advances of nanobody applications in diagnosis and detection","volume":"2","author":"Su","year":"2023","journal-title":"MedComm \u2013 Biomaterials and Applications"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.004","article-title":"Nanobodies as efficient drug-carriers: progress and trends in chemotherapy","volume":"334","author":"Panikar","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0070","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1016\/j.apsb.2024.03.016","article-title":"Single-domain antibodies as therapeutics for solid tumor treatment","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1697","article-title":"Nanobody-a versatile tool for cancer diagnosis and therapeutics","volume":"13","author":"Liu","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid single-domain antibodies: historical perspective and future outlook","volume":"8","author":"Arbabi-Ghahroudi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0095","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.2147\/IJN.S107194","article-title":"Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications","volume":"11","author":"Wang","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features and therapeutic potential","volume":"45","author":"Konning","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0110","series-title":"Current Protocols in Protein Science, Chapter 6","article-title":"Overview on concepts and applications of Fab antibody fragments","author":"Rader","year":"2009"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1084\/jem.127.3.431","article-title":"Papain digestion fragments of human IgM globulins","volume":"127","author":"Mihaesco","year":"1968","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0022-2836(88)90214-8","article-title":"Expression of an antibody Fv fragment in myeloma cells","volume":"203","author":"Riechmann","year":"1988","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0968-0004(01)01790-X","article-title":"Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains","volume":"26","author":"Muyldermans","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function:the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-0716-2609-2_2","article-title":"Structural classification of CDR-H3 in single-domain V(H)H antibodies","volume":"2552","author":"Kuroda","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0145","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1039\/D2NR00306F","article-title":"Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development","volume":"14","author":"Li","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0150","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/19420862.2018.1489633","article-title":"Antigen recognition by single-domain antibodies: structural latitudes and constraints","volume":"10","author":"Henry","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.963978","article-title":"Research progress and applications of nanobody in human infectious diseases","volume":"13","author":"Mei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","article-title":"Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2","volume":"370","author":"Xiang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0165","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","article-title":"The structural basis of nanobody unfolding reversibility and thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0161-5890(97)00146-6","article-title":"Comparison of llama VH sequences from conventional and heavy chain antibodies","volume":"34","author":"Vu","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0175","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1038\/s41598-023-41525-3","article-title":"Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli","volume":"13","author":"Tungekar","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/bioengineering10020122","article-title":"Bioengineering of antibody fragments: challenges and opportunities","volume":"10","author":"Pirkalkhoran","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/nnm.14.178","article-title":"Nanobody-based cancer therapy of solid tumors","volume":"10","author":"Kijanka","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","article-title":"Identification and in vivo characterization of a brain-penetrating nanobody","volume":"17","author":"Wouters","year":"2020","journal-title":"Fluid. Barriers of the CNS"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0195","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0200","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/toxins11080464","article-title":"Camelid VHHs fused to human fc fragments provide long term protection against botulinum neurotoxin a in mice","volume":"11","author":"Godakova","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0205","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.7150\/thno.57510","article-title":"Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice","volume":"11","author":"Xenaki","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150454","article-title":"Structural design of the anti-TNF\u03b1 therapeutic NANOBODY\u00ae compound, ozoralizumab, to support its potent and sustained clinical efficacy","volume":"734","author":"Mima","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111553","article-title":"Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation","volume":"223","author":"Li","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies","volume":"414","author":"Arbabi Ghahroudi","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/bi0009082","article-title":"Thermal unfolding of a llama antibody fragment: a two-state reversible process","volume":"40","author":"P\u00e9rez","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0230","first-page":"277","article-title":"Single domain camel antibodies: current status","volume":"74","author":"Muyldermans","year":"2001","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202208773","article-title":"Chemoenzymatic synthesis of a rhamnose-functionalized bispecific nanobody as a bispecific antibody mimic for cancer immunotherapy","volume":"61","author":"Hong","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0250","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ni.2621","article-title":"Matching cellular dimensions with molecular sizes","volume":"14","author":"Reth","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0255","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1116\/1.589112","article-title":"Covalent immobilization of immunoglobulins G and Fab\u2019 fragments on gold substrates for scanning force microscopy imaging in liquids","volume":"14","author":"Droz","year":"1996","journal-title":"J. Vacuum Sci. & Technol. B: Microelectron. Nanomet. Structures Processing, Measurement, and Phenomena"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0270","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0275","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1002\/bit.27944","article-title":"A comparative analysis of recombinant fab and full-length antibody production in Chinese hamster ovary cells","volume":"118","author":"Hussain","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0280","doi-asserted-by":"crossref","first-page":"2300076","DOI":"10.1002\/adtp.202300076","article-title":"Self-immolative nanobody-cysteine residue modification for controlled immunodrug delivery","volume":"6","author":"Scherger","year":"2023","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0285","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/cm402180t","article-title":"The thiol-michael addition click reaction: a powerful and widely used tool in materials chemistry","volume":"26","author":"Nair","year":"2013","journal-title":"Chem. Mater."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0290","article-title":"NanoB2 to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET","volume":"3","author":"van den Bor","year":"2023","journal-title":"Cell REP Meth."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0295","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41467-018-03191-2","article-title":"A peptide tag-specific nanobody enables high-quality labeling for dSTORM imaging","volume":"9","author":"Virant","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.142941","article-title":"Engineered synthetic nanobody-based biosensors for electrochemical detection of epidermal growth factor receptor","volume":"465","author":"Cruz-Pacheco","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0305","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jps.20098","article-title":"Current methods for attaching targeting ligands to liposomes and nanoparticles","volume":"93","author":"Nobs","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0310","article-title":"Antibody-incorporated nanomedicines for cancer therapy","volume":"34","author":"Wu","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0315","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1007\/s00018-020-03753-y","article-title":"PDGF receptor mutations in human diseases","volume":"78","author":"Gu\u00e9rit","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0320","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cub.2021.08.039","article-title":"Protein sorting: a new quality control pathway for GPI-anchored proteins","volume":"31","author":"Klemm","year":"2021","journal-title":"Curr. Biol.\u202f: CB"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0325","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1073\/pnas.91.13.6245","article-title":"Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses","volume":"91","author":"Bergelson","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0330","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1074\/jbc.M705195200","article-title":"Crystal structure of lactadherin C2 domain at 1.7A resolution with mutational and computational analyses of its membrane-binding motif","volume":"283","author":"Shao","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0335","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/ja039915e","article-title":"Sortase-mediated protein ligation: a new method for protein engineering","volume":"126","author":"Mao","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0340","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/acs.bioconjchem.3c00037","article-title":"OaAEP1 ligase-assisted chemoenzymatic synthesis of full cysteine-rich metal-binding cyanobacterial metallothionein smtA","volume":"34","author":"Antonenko","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0345","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc500099v","article-title":"Versatility of microbial transglutaminase","volume":"25","author":"Strop","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0350","doi-asserted-by":"crossref","first-page":"31053","DOI":"10.3402\/jev.v5.31053","article-title":"Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting","volume":"5","author":"Kooijmans","year":"2016","journal-title":"J. Extracell Vesicl."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0355","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: how did we start and where are we now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0360","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0365","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0370","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy","volume":"9","author":"van der Veeken","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0375","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.12.027","article-title":"Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment","volume":"159","author":"van der Meel","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0380","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0385","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0390","article-title":"Camouflaged liposomes by 11A4-nanobody for co-delivery of cisplatin and nitroxoline in breast cancer tumors: an in vitro\/in vivo study","volume":"71","author":"Sayed-Tabatabaei","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0395","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","article-title":"Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1\/PD-L1 and regulatory pathways","volume":"13","author":"Wang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0400","first-page":"681","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0405","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Report. Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201802372","article-title":"Remodeling tumor-associated macrophages and neovascularization overcomes EGFRT790M-associated drug resistance by PD-L1 nanobody-mediated codelivery","volume":"14","author":"Yin","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0415","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.7150\/thno.42234","article-title":"BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation","volume":"10","author":"Yin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120187","article-title":"Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery","volume":"255","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0425","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12951-024-02781-1","article-title":"A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects","volume":"22","author":"Xie","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0430","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0435","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41419-023-05914-w","article-title":"A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejpb.2018.09.017","article-title":"Sortaggable liposomes: evaluation of reaction conditions for single-domain antibody conjugation by sortase-a and targeting of CD11b(+) myeloid cells","volume":"133","author":"W\u00f6ll","year":"2018","journal-title":"Eur. J. Pharmaceut. Biopharmaceut.: Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0445","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41565-024-01620-6","article-title":"Chimeric nanobody-decorated liposomes by self-assembly","volume":"19","author":"Rahman","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0450","article-title":"Engineered extracellular vesicles for cancer therapy","volume":"33","author":"Zhang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113910","article-title":"Extracellular vesicles as delivery systems at nano\u2212\/micro-scale","volume":"179","author":"Fu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"vol. 9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0465","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2024.03.007","article-title":"Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases","volume":"368","author":"Li","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0470","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12575-023-00220-3","article-title":"Extracellular vesicles for drug delivery in cancer treatment","volume":"25","author":"Wang","year":"2023","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.734720","article-title":"Development of extracellular vesicle therapeutics: challenges, considerations, and opportunities","volume":"9","author":"Claridge","year":"2021","journal-title":"Front. Cell Development. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216960","article-title":"Revisiting the advances and challenges in the clinical applications of extracellular vesicles in cancer","volume":"593","author":"He","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12929-022-00798-y","article-title":"Application of engineered extracellular vesicles for targeted tumor therapy","volume":"29","author":"Zhang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0490","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Kimiz-Gebologlu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12057","article-title":"Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery","volume":"10","author":"Pham","year":"2021","journal-title":"J. Extracell Vesicl."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0500","first-page":"1302","article-title":"Molecular lipidomics of exosomes released by PC-3 prostate cancer cells","volume":"2013","author":"Llorente","year":"1831","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0505","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.cell.2012.11.024","article-title":"Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration","volume":"151","author":"Luga","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0510","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.7150\/thno.17602","article-title":"Tumor-triggered drug release from calcium carbonate-encapsulated gold nanostars for near-infrared photodynamic\/photothermal combination antitumor therapy","volume":"7","author":"Liu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0515","doi-asserted-by":"crossref","first-page":"2209393","DOI":"10.1002\/adfm.202209393","article-title":"Surface-engineered extracellular vesicles with CDH17 nanobodies to efficiently deliver imaging probes and chemo-photothermal drugs for gastric cancer theragnostic","volume":"33","author":"Xia","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0520","article-title":"Engineered cellular vesicles displaying glycosylated nanobodies for cancer immunotherapy","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0525","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jconrel.2023.11.013","article-title":"An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy","volume":"364","author":"Gong","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2016.01.009","article-title":"PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time","volume":"224","author":"Kooijmans","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0535","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1039\/C7NR06966A","article-title":"Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach","volume":"10","author":"Kooijmans","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0540","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12187","article-title":"Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy","volume":"11","author":"Peng","year":"2022","journal-title":"J. Extracell Vesicl."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0545","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2023.12.058","article-title":"Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer","volume":"366","author":"Chen","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0550","doi-asserted-by":"crossref","first-page":"114","DOI":"10.32607\/actanaturae.11478","article-title":"Targeting extracellular vesicles to dendritic cells and macrophages","volume":"13","author":"Ovchinnikova","year":"2021","journal-title":"Acta Nat."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15674","article-title":"Sonication is a suitable method for loading nanobody into glioblastoma small extracellular vesicles","volume":"9","author":"Colja","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0560","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.tifs.2021.06.001","article-title":"Self-assembled micelles based on amphiphilic biopolymers for delivery of functional ingredients","volume":"114","author":"Bu","year":"2021","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0565","first-page":"19","article-title":"Preparation and characterization of micelles","volume":"2019","author":"Patravale","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0570","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/polym14122510","article-title":"A review of polymeric micelles and their applications","volume":"14","author":"Perumal","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0575","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","article-title":"Block copolymer micelles in nanomedicine applications","volume":"118","author":"Cabral","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0580","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0585","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2011.06.003","article-title":"Reprint of \u201cNanobody \u2014 Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting\u201d","volume":"153","author":"Talelli","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0590","doi-asserted-by":"crossref","first-page":"30297","DOI":"10.1021\/acsami.7b05654","article-title":"Quantum-dot-based theranostic micelles conjugated with an anti-EGFR nanobody for triple-negative breast cancer therapy","volume":"9","author":"Wang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0595","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1021\/acs.molpharmaceut.9b01280","article-title":"EGFR-targeted nanobody functionalized polymeric micelles loaded with mTHPC for selective photodynamic therapy","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0600","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1098\/rstb.2001.1023","article-title":"Elastin: a representative ideal protein elastomer, philosophical transactions of the Royal Society of London","volume":"357","author":"Urry","year":"2002","journal-title":"Series B, Biol. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0605","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.biomac.6b01759","article-title":"Phase behavior and self-assembly of perfectly sequence-defined and monodisperse multiblock copolypeptides","volume":"18","author":"MacEwan","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0610","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/protein\/gzh006","article-title":"Effect of protein fusion on the transition temperature of an environmentally responsive elastin-like polypeptide: a role for surface hydrophobicity? Protein engineering, design & selection","volume":"17","author":"Trabbic-Carlson","year":"2004","journal-title":"PEDS"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1021\/acs.nanolett.8b03837","article-title":"Active targeting of cancer cells by nanobody decorated polypeptide micelle with bio-orthogonally conjugated drug","volume":"19","author":"Costa","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0620","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2021.12.030","article-title":"Evolution of drug delivery systems: from 1950 to 2020 and beyond","volume":"342","author":"Park","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0625","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00044-021-02748-z","article-title":"Albumin roles in developing anticancer compounds","volume":"30","author":"Ribeiro","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0630","doi-asserted-by":"crossref","first-page":"1329636","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0635","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0640","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2024.02.004","article-title":"Biomimetic nano-chelate diethyldithiocarbamate cu\/Fe for enhanced metalloimmunity and ferroptosis activation in glioma therapy","volume":"368","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0645","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1039\/C8NR08951E","article-title":"Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy","volume":"11","author":"Chang","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.779591","article-title":"CuS@BSA-NB2 nanoparticles for HER2-targeted photothermal therapy","volume":"12","author":"Ying","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0655","first-page":"501","article-title":"Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET","volume":"6","author":"Naldini","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0660","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.biomaterials.2013.10.001","article-title":"Targeting hepatocyte growth factor receptor (met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles","volume":"35","author":"Heukers","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0665","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0670","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1039\/C7TB03132G","article-title":"Transglutaminase mediated PEGylation of nanobodies for targeted nano-drug delivery","volume":"6","author":"Wu","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0675","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ac07d1","article-title":"Moderating hypoxia and promoting immunogenic photodynamic therapy by HER-2 nanobody conjugate nanoparticles for ovarian cancer treatment","volume":"32","author":"Zhang","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0680","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fchem.2019.00167","article-title":"Gold nanoparticles for photothermal cancer therapy","volume":"7","author":"Vines","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1021\/nn901392m","article-title":"Quantifying the cellular uptake of antibody-conjugated Au nanocages by two-photon microscopy and inductively coupled plasma mass spectrometry","volume":"4","author":"Au","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0690","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/nn1023363","article-title":"Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy","volume":"5","author":"Van de Broek","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0695","first-page":"2749","article-title":"Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells","volume":"6","author":"Fekrazad","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0700","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/nn1023363","article-title":"Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy","volume":"5","author":"Van de Broek","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0705","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0710","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.3390\/ijms22179118","article-title":"Targeted delivery of drugs and genes using polymer nanocarriers for cancer therapy","volume":"22","author":"Xia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0715","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0720","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1021\/acs.molpharmaceut.8b01318","article-title":"Selective cytotoxicity to HER2 positive breast cancer cells by saporin-loaded nanobody-targeted polymeric nanoparticles in combination with photochemical internalization","volume":"16","author":"Mart\u00ednez-Jothar","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0725","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jbiotec.2015.09.034","article-title":"Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study","volume":"214","author":"Zou","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0730","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0735","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s11696-022-02625-y","article-title":"Anti-MUC1 nanobody conjugated by chitosan nanoparticle with enhancement of anti-proliferation activity in breast cancer cell lines","volume":"77","author":"Khodabakhsh","year":"2023","journal-title":"Chem. Pap."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0740","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1039\/D2MA00082B","article-title":"Dual CEA\/CD44 targeting to colorectal cancer cells using nanobody-conjugated hyaluronic acid-modified mesoporous silica nanoparticles with pH- and redox-sensitivity","volume":"3","author":"Fan","year":"2022","journal-title":"Mater. Adv."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0745","first-page":"7442","article-title":"Nanobody-ferritin conjugate for targeted photodynamic therapy, chemistry \u2013 a","volume":"26","author":"Liu","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120870","article-title":"Nanobody modified high-performance AIE photosensitizer nanoparticles for precise photodynamic oral cancer therapy of patient-derived tumor xenograft","volume":"274","author":"Wu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0755","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1039\/D0BM01335H","article-title":"Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin","volume":"9","author":"Tieu","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0760","article-title":"Enhancing tumor immunotherapy by multivalent anti-PD-L1 nanobody assembled via ferritin nanocage","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0765","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0770","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/cancers15061845","article-title":"Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0775","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41587-024-02168-5","article-title":"Cancer-targeting antibody\u2013drug conjugates drive dealmaking frenzy","volume":"42","author":"Senior","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0780","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/genes13112065","article-title":"Antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"13","author":"Najjar","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0785","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0790","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cbpa.2013.01.004","article-title":"Targeted delivery of platinum-based anticancer complexes","volume":"17","author":"Butler","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0795","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12951-025-03169-5","article-title":"Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0800","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/nnm.14.178","article-title":"Nanobody-based cancer therapy of solid tumors","volume":"10","author":"Kijanka","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0805","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00253-017-8644-3","article-title":"Expression of single-domain antibody in different systems","volume":"102","author":"Liu","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0810","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1039\/D2NR00306F","article-title":"Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development","volume":"14","author":"Li","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0815","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12951-024-02521-5","article-title":"A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer","volume":"22","author":"Wu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0820","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41467-024-51253-5","article-title":"Self-reporting photodynamic nanobody conjugate for precise and sustainable large-volume tumor treatment","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0825","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","article-title":"A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models","volume":"6","author":"Fan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0830","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0835","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1039\/D0CC03396K","article-title":"Clustered nanobody\u2013drug conjugates for targeted cancer therapy","volume":"56","author":"Wu","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0840","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004590","article-title":"PD-L1\/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way","volume":"10","author":"Yu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111553","article-title":"Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation","volume":"223","author":"Li","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0850","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/anie.201509432","article-title":"Structurally defined \u03b1MHC-II nanobody-drug conjugates: a therapeutic and imaging system for B-cell lymphoma","volume":"55","author":"Fang","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0855","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0860","doi-asserted-by":"crossref","first-page":"2004574","DOI":"10.1002\/advs.202004574","article-title":"Targeted repolarization of tumor-associated macrophages via imidazoquinoline-linked nanobodies","volume":"8","author":"Bolli","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0865","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biom13071042","article-title":"Nanobody-based EGFR-targeting immunotoxins for colorectal cancer treatment","volume":"13","author":"Narbona","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0870","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.apsb.2024.08.023","article-title":"A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy","volume":"14","author":"Xi","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0875","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.3390\/ijms22115501","article-title":"A single-domain antibody-based anti-PSMA recombinant immunotoxin exhibits specificity and efficacy for prostate cancer therapy","volume":"22","author":"Xing","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0880","first-page":"637","article-title":"A novel immunotoxin targeting epithelial cell adhesion molecule using single domain antibody fused to diphtheria toxin","volume":"65","author":"Roshan","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0885","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/IJN.S399322","article-title":"(131)I-labeled anti-HER2 nanobody for targeted radionuclide therapy of HER2-positive breast cancer","volume":"18","author":"Zhao","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0890","doi-asserted-by":"crossref","first-page":"77","DOI":"10.34133\/research.0077","article-title":"Development and characterization of nanobody-derived CD47 theranostic pairs in solid tumors","volume":"6","author":"Zhang","year":"2023","journal-title":"Research"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0895","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1007\/s00432-023-04793-0","article-title":"In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody","volume":"149","author":"Zhu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0900","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/acs.bioconjchem.2c00209","article-title":"IgG-binding nanobody capable of prolonging nanobody-based radiotracer plasma half-life and enhancing the efficacy of tumor-targeted radionuclide therapy","volume":"33","author":"Hu","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0905","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with a 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"D\u2019Huyvetter","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0910","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12951-024-03008-z","article-title":"Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy","volume":"22","author":"Dewulf","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acs.bioconjchem.0c00578","article-title":"Synthetic tuning of domain stoichiometry in nanobody-enzyme megamolecules","volume":"32","author":"Metcalf","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0920","first-page":"597675","article-title":"A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by affecting tumor associated macrophages","author":"Tong","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0925","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1039\/C9CC01391A","article-title":"Modular design of nanobody\u2013drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent","volume":"55","author":"Huang","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0930","first-page":"579","article-title":"Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1","author":"Ziaei","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0935","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0940","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0945","doi-asserted-by":"crossref","first-page":"eabq4419","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0950","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0955","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0960","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs : Clin. Immunotherapeut. Biopharmaceut. Gene Therap."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0965","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/nnm.12.3","article-title":"Challenges posed by the scale-up of nanomedicines","volume":"7","author":"Muthu","year":"2012","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2025.02.058_bb0970","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/164_2019_312","article-title":"The evolving landscape of cancer therapeutics","volume":"260","author":"Khan","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0975","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1021\/acs.bioconjchem.3c00302","article-title":"Site-specific antibody conjugation using modified bisected N-glycans: method development and potential toward tunable effector function","volume":"34","author":"Hsu","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.02.058_bb0980","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/acs.bioconjchem.8b00680","article-title":"Proximity-induced site-specific antibody conjugation","volume":"29","author":"Yu","year":"2018","journal-title":"Bioconjug. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:52:42Z","timestamp":1769219562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":196,"alternative-id":["S0168365925001713"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.058","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody-based drug delivery systems for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113562"}}